ALX148 clinical trials
Also written ALX148 and evorpacept.
How each study uses ALX148 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ALX148 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 5
ALX Oncology Inc. (8) · M.D. Anderson Cancer Center (1) · Alexander B Olawaiye, MD (1) · University of California, San Diego (1) · Jazz Pharmaceuticals (1) · QuantumLeap Healthcare Collaborative (1) · University of Colorado, Denver (1)
Often tested with
Tested in the same studies.
Zanidatamab (2) · MicroRNA-10b Antagomir-Iron Oxide/Dextran-based Nanoparticle TTX-MC138 (1)
Studies
Open first, then newest update. How each study uses ALX148 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerRecruitingPhase 2ALX Oncology Inc.NCT07007559Written as Evorpacept (ALX148)
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingPhase 1/2QuantumLeap Healthcare CollaborativeNCT05868226Written as ALX148
- A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)CompletedPhase 2/3ALX Oncology Inc.NCT05002127Written as Evorpacept (ALX148)
- ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT05025800Written as CD47 Antagonist ALX148
- Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerTerminatedPhase 2University of Colorado, DenverNCT05167409Written as Evorpacept (ALX148)
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian CancerActive, not recruitingPhase 2Alexander B Olawaiye, MDNCT05467670Written as ALX148
- Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)Active, not recruitingPhase 2University of California, San DiegoNCT05787639Written as Evorpacept
- A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing CancerCompletedPhase 1/2Jazz PharmaceuticalsNCT05027139Written as Evorpacept
- Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)Active, not recruitingPhase 2ALX Oncology Inc.NCT04675333Written as evorpacept
- Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)Active, not recruitingPhase 2ALX Oncology Inc.NCT04675294Written as evorpacept
- A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)CompletedPhase 1ALX Oncology Inc.NCT03013218Written as Evorpacept (ALX148)
- A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)CompletedPhase 1ALX Oncology Inc.NCT05524545Written as Evorpacept
- A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)TerminatedPhase 1ALX Oncology Inc.NCT04417517Written as evorpacept
- A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)TerminatedPhase 1ALX Oncology Inc.NCT04755244Written as evorpacept
Given beside what is tested · 1 — ALX148 is usual care or a partner of the new treatment
Codes
What other systems call ALX148 · ClinicalTrials.gg INT001498
- MeSH (NLM) C000712178ALX148One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712178 | ALX148 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.